Evidence map›Paper›PMID 41286461›Full record

ReviewApplied microbiology and biotechnology2025

MiRNA-based drugs: challenges and delivery strategies.

Ziyu Wang, Yingyuan Peng, Haifeng Zhou, Min Zhang, Dianwen Ju, Zhilong Chen

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Applied microbiology and biotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
35citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

35 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Review
  5. Review
  6. Article
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
  12. Review
  13. Article
  14. Review
  15. Article
  16. Article
  17. Review
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Ziyu WangDepartment of Pharmacy, Huadong Hospital, Fudan University, Shanghai, 200040, China.
Yingyuan PengDepartment of Pharmacy, Huadong Hospital, Fudan University, Shanghai, 200040, China.
Haifeng ZhouDepartment of Pharmacy, Huadong Hospital, Fudan University, Shanghai, 200040, China.
Min ZhangDepartment of Pharmacy, Huadong Hospital, Fudan University, Shanghai, 200040, China.
Dianwen JuDepartment of Biological Medicines and Shanghai Engineering Research Center of Immunotherapeutics, Fudan University School of Pharmacy, Shanghai, 201203, China. dianwenju@fudan.edu.cn.
Zhilong ChenDepartment of Pharmacy, Huadong Hospital, Fudan University, Shanghai, 200040, China. chenzhilong@fudan.edu.cn.

Funding

Foundation of Shanghai Science and Technology Committee 21430730100, 23S11901600, 21MC1930200National Natural Science Foundation of China 22361132541RSF grant 24-45-00020the grant of Fudan University IDF163011Zhongguancun Precision Medicine Foundation ZGC-YXKJ-25
6 · The paper itself

Abstract

The miRNA-based therapeutics held great promise for the treatment of diseases associated with aberrant gene expression. However, the development of miRNA-based drugs still faces many obstacles, including stability, targetability, tissue penetration, and induction of immune responses. To overcome these challenges, researchers developed various miRNA modification methods and miRNA-based delivery systems, which can protect miRNA from degradation and facilitate their transport across biological barriers. Here, we give an overview of the latest advancements in a variety of delivery systems, including virus, lipid, polymer, inorganic, and exosome-based nanosystems, which have been proved as versatile and valuable carriers for miRNA. Moreover, the use of stimuli-responsive materials allows for the controlled release of oligonucleotides in response to specific triggers. Importantly, the current miRNA-based therapeutics in clinical trials are summarized in this review. The combination of these advancements has the potential to promote more effective and safer treatment designs for a wide range of diseases. This review will contribute to developing more precise targeted delivery systems of miRNA, ultimately facilitating its clinical development.

Indexed as

Drug Delivery SystemsMicroRNAsAnimalsDrug CarriersHumansDrug CarriersMicroRNAsChemical modificationDelivery systemsMicroRNA-based therapyStimuli-responsive materials

Identifiers

PMID41286461
PMCPMC12647180

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.